Skip to main content

Table 1 Liver attenuation and liver enzymes by steatosis/steatohepatitis status

From: Immune checkpoint inhibitors and their impact on liver enzymes and attenuation

 

Overall (n = 81)

Steatosis/Steatohepatitis

Liver attenuation (HU)

 

Yes (n = 11)

No (n = 70)

p value – Between groups

Baseline

58.44

46.67

60.29

 < 0.001*

Post-treatment

60.60

54.83

61.51

0.460

∆ Post-treatment/Baseline

2.17

8.16

1.22

0.165

p value – ∆ Post-treatment/Baseline

0.055

0.103

0.247

-

 

Overall (n = 101)

Steatosis/Steatohepatitis

Liver enzymes (AST)

 

Yes (n = 31)

No (n = 70)

p value – Between groups

Baseline

27.57

37.74

23.07

0.003*

Post-treatment

22.92

26.35

21.40

0.014

Last follow up

26.12

31.19

23.40

0.057

∆ Post-treatment/Baseline

-4.75

-11.39

-1.67

0.044

p value – ∆ Post-treatment/Baseline

0.005*

0.018

0.114

-

 

Overall (n = 101)

Steatosis/Steatohepatitis

Liver enzymes (ALT)

 

Yes (n = 31)

No (n = 70)

p value – Between groups

Baseline

28.76

45.52

21.34

0.007*

Post-treatment

24.20

32.03

20.73

0.009*

Last follow up

25.28

28.13

24.03

0.332

∆ Post-treatment/Baseline

-4.75

-13.48

-0.61

0.093

p value – ∆ Post-treatment/Baseline

0.076

0.073

0.710

-

  1. Note. Statistical comparisons were conducted with independent t-tests for intergroup comparisons and paired t-tests for intragroup comparisons. HU Hounsfield unit
  2. *Statistically significant at p < 0.05/k (k = number of tests performed) after Bonferroni correction for multiple testing